PURPOSE: To assess the clinical significance of the interaction between estrogen and Runx2 signaling, previously shown in vitro. EXPERIMENTAL DESIGN: MCF7/Rx2(dox) breast cancer cells were treated with estradiol and/or doxycycline to induce Runx2, and global gene expression was profiled to define genes regulated by estradiol, Runx2, or both. Anchorage-independent growth was assessed by soft-agar colony formation assays. Expression of gene sets defined using the MCF7/Rx2(dox) system was analyzed in pre- and on-treatment biopsies from hormone receptor-positive patients undergoing neoadjuvant letrozole treatment in two independent studies, and short-term changes in gene expression were correlated with tumor size reduction or Ki67 index at surgery. RESULTS: Reflecting its oncogenic property, estradiol strongly promoted soft-agar colony formation, whereas Runx2 blocked this process suggesting tumor suppressor property. Transcriptome analysis of MCF7/Rx2(dox) cells treated with estradiol and/or doxycycline showed reciprocal attenuation of Runx2 and estrogen signaling. Correspondingly in breast cancer tumors, expression of estradiol- and Runx2-regulated genes was inversely correlated, and letrozole increased expression of Runx2-stimulated genes, as defined in the MCF7/Rx2(dox) model. Of particular interest was a gene set upregulated by estradiol and downregulated by Runx2 in vitro; its short-term response to letrozole treatment associated with tumor size reduction and Ki67 index at surgery better than other estradiol-regulated gene sets. CONCLUSION: This work provides clinical evidence for the importance of antagonism between Runx2 and E2 signaling in breast cancer. Likely sensing the tension between them, letrozole responsiveness of a genomic node, positively regulated by estradiol and negatively regulated by Runx2 in vitro, best correlated with the clinical efficacy of letrozole treatment.
PURPOSE: To assess the clinical significance of the interaction between estrogen and Runx2 signaling, previously shown in vitro. EXPERIMENTAL DESIGN:MCF7/Rx2(dox) breast cancer cells were treated with estradiol and/or doxycycline to induce Runx2, and global gene expression was profiled to define genes regulated by estradiol, Runx2, or both. Anchorage-independent growth was assessed by soft-agar colony formation assays. Expression of gene sets defined using the MCF7/Rx2(dox) system was analyzed in pre- and on-treatment biopsies from hormone receptor-positive patients undergoing neoadjuvant letrozole treatment in two independent studies, and short-term changes in gene expression were correlated with tumor size reduction or Ki67 index at surgery. RESULTS: Reflecting its oncogenic property, estradiol strongly promoted soft-agar colony formation, whereas Runx2 blocked this process suggesting tumor suppressor property. Transcriptome analysis of MCF7/Rx2(dox) cells treated with estradiol and/or doxycycline showed reciprocal attenuation of Runx2 and estrogen signaling. Correspondingly in breast cancer tumors, expression of estradiol- and Runx2-regulated genes was inversely correlated, and letrozole increased expression of Runx2-stimulated genes, as defined in the MCF7/Rx2(dox) model. Of particular interest was a gene set upregulated by estradiol and downregulated by Runx2 in vitro; its short-term response to letrozole treatment associated with tumor size reduction and Ki67 index at surgery better than other estradiol-regulated gene sets. CONCLUSION: This work provides clinical evidence for the importance of antagonism between Runx2 and E2 signaling in breast cancer. Likely sensing the tension between them, letrozole responsiveness of a genomic node, positively regulated by estradiol and negatively regulated by Runx2 in vitro, best correlated with the clinical efficacy of letrozole treatment.
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: B Huang; Z Qu; C W Ong; Y-H N Tsang; G Xiao; D Shapiro; M Salto-Tellez; K Ito; Y Ito; L-F Chen Journal: Oncogene Date: 2011-06-27 Impact factor: 9.867
Authors: Joshua D Stender; Kyuri Kim; Tze Howe Charn; Barry Komm; Ken C N Chang; W Lee Kraus; Christopher Benner; Christopher K Glass; Benita S Katzenellenbogen Journal: Mol Cell Biol Date: 2010-06-14 Impact factor: 4.272
Authors: Torsten O Nielsen; Joel S Parker; Samuel Leung; David Voduc; Mark Ebbert; Tammi Vickery; Sherri R Davies; Jacqueline Snider; Inge J Stijleman; Jerry Reed; Maggie C U Cheang; Elaine R Mardis; Charles M Perou; Philip S Bernard; Matthew J Ellis Journal: Clin Cancer Res Date: 2010-09-13 Impact factor: 12.531
Authors: Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel Journal: Mol Cancer Date: 2010-09-23 Impact factor: 27.401
Authors: Moran Choe; Jessica L Brusgard; Saranya Chumsri; Lekhana Bhandary; Xianfeng Frank Zhao; Song Lu; Olga G Goloubeva; Brian M Polster; Gary M Fiskum; Geoffrey D Girnun; Myoung Sook Kim; Antonino Passaniti Journal: J Cell Biochem Date: 2015-10 Impact factor: 4.429
Authors: Gillian Browne; Hanna Taipaleenmäki; Nicole M Bishop; Sharath C Madasu; Leslie M Shaw; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian Journal: J Cell Physiol Date: 2015-10 Impact factor: 6.384
Authors: A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein Journal: Genes Chromosomes Cancer Date: 2019-03-15 Impact factor: 5.006
Authors: Yonatan Amzaleg; Jie Ji; Donlaporn Kittivanichkul; Anna E Törnqvist; Sara Windahl; Elias Sabag; Aysha B Khalid; Hal Sternberg; Michael West; John A Katzenellenbogen; Susan A Krum; Nyam-Osor Chimge; Dustin E Schones; Yankel Gabet; Claes Ohlsson; Baruch Frenkel Journal: J Steroid Biochem Mol Biol Date: 2018-05-08 Impact factor: 4.292